Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-491 versus ramipril in essential hypertension
2007-002583-10Phase 3Completed
- Sponsor
- Takeda
- Start
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in essential hypertension comparing TAK-491 with ramipril (2 arms). Primary endpoint: Change from baseline in sitting trough clinic systolic blood pressure. Started Nov 2007; status: completed.
02
Drugs
azilsartan medoxomilramipril
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2007-002583-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002583-10.